Approaches to therapy for pulmonary hypertension: Role of the endothelin receptor antagonist bosentan

• Published in: Terapevtic̆eskii arhiv Vol. 87; no. 9; pp. 64 - 71
• Main Author: Avdeev, S N
• Format: Journal Article
• Language: Russian
• Published: Russia (Federation) "Consilium Medicum" Publishing house 2015
• Subjects: Antihypertensive Agents - pharmacology; bosentan; Clinical Trials as Topic; endothelin receptor antagonists; Endothelin Receptor Antagonists - pharmacology; Humans; Hypertension, Pulmonary - diagnosis; Hypertension, Pulmonary - drug therapy; Hypertension, Pulmonary - etiology; Hypertension, Pulmonary - physiopathology; Outcome Assessment (Health Care); Prognosis; Pulmonary Circulation - drug effects; pulmonary hypertension; Sulfonamides - pharmacology; Vascular Resistance - drug effects
• ISSN: 0040-3660; 2309-5342
• DOI: 10.17116/terarkh201587964-71

Pulmonary hypertension (PH) is a specific clinical group of severe and rare diseases with similar morphological, hemodynamic, and therapeutic characteristics. Despite the fact that there have been international conciliative documents and advances in drug therapy for PH, the long-term prognosis of the.disease in these patients remains rather poor. Clinical trials have demonstrated that bosentan therapy in patients with PH improves pulmonary hemodynamics and exercise endurance and delays the development of the disease. According to the data of long-term studies, as compared to the historical control, bosentan used as a first-line drug can improve survival in PH patients.